Sanofi and Boehringer Complete Swap

(c) Boehringer Ingelheim
(c) Boehringer Ingelheim

French drugmaker Sanofi and German pharmaceutical company Boehringer Ingelheim have completed their business swap, which sees Sanofi take Boehringer’s consumer healthcare (CHC) business in exchange for its own Merial animal health division.

The deal, first announced in December 2015, closed on Jan. 1, 2017 in most markets. The acquisition of Merial in Mexico and the Merial and the CHC swap in India have been delayed pending receipt of certain regulatory approvals, but both are expected to close early in 2017.

The European Commission cleared the transaction in November 2016 after Boehringer agreed to sell some of Merial’s vaccines and pharmaceuticals, allaying the regulator’s concerns about reduced competition and the possibility of higher prices. The products to be divested include vaccines Circovac, Progressis, Parvovax, Parvovurax and Mucossifa and pharmaceuticals Ketofen, Wellicox, Allevinix, Genixine and the injectable and paste versions of Equioxx.

Sanofi’s CEO, Olivier Brandicourt, said the integration of Boehringer’s CHC assets allows the Paris-based group to enhance its positions in core strategic categories in a promising market.

Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, said the combined strength of the two organizations will improve the German firm’s competitiveness in the strategically important animal health business.

The companies said last June that the $20 billion mutually beneficial swap will lay the foundation for both to reach the size and scale required in two highly attractive businesses. Lyon and Toulouse in France will be key operational centers of Boehringer’s animal health business, while Germany will be an important part of Sanofi’s CHC operations, focusing on gastrointestinal and cough & cold categories in particular.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.